← Back to Screener
Iridex Corp (IRIX)
Price$1.12
Value ScoreB
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)12.71%
Price vs S&P 500 (4W)12.28%
VGM Score53.08
Market Capitalization$19.67M
All Metrics
Book Value / Share (Quarterly)$0.27
P/TBV (Annual)5.33x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.58%
Cash Flow / Share (Quarterly)$-0.15
Price vs S&P 500 (YTD)-9.94%
Gross Margin (TTM)35.97%
Net Profit Margin (TTM)-6.23%
EPS (TTM)$-0.19
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$-0.19
Revenue Growth (5Y)7.70%
EPS (Annual)$-0.26
ROI (Annual)-51.25%
Gross Margin (Annual)36.50%
Net Profit Margin (5Y Avg)-13.63%
Cash / Share (Quarterly)$0.26
Revenue Growth QoQ (YoY)-0.82%
ROA (Last FY)-15.22%
Revenue Growth TTM (YoY)7.73%
EBITD / Share (TTM)$-0.13
ROE (5Y Avg)-136.36%
Operating Margin (TTM)-5.12%
Cash Flow / Share (Annual)$-0.13
P/B Ratio4.16x
P/B Ratio (Quarterly)3.66x
Net Income / Employee (Annual)$-47,700
EV / Revenue (TTM)0.36x
Net Interest Coverage (TTM)76.00x
ROA (TTM)-11.16%
EV / EBITDA (TTM)19.83x
EPS Incl Extra (Annual)$-0.26
Current Ratio (Annual)1.91x
Quick Ratio (Quarterly)1.01x
3-Month Avg Trading Volume0.20M
52-Week Price Return20.42%
Revenue / Employee (TTM)$565,400
Tangible BV / Share (Quarterly)$0.22
P/S Ratio (Annual)0.37x
Asset Turnover (Annual)1.81x
52-Week High$1.65
Operating Margin (5Y Avg)-12.76%
EPS Excl Extra (Annual)$-0.26
CapEx CAGR (5Y)7.42%
Tangible BV CAGR (5Y)-25.62%
26-Week Price Return20.51%
Quick Ratio (Annual)1.18x
13-Week Price Return-16.42%
Total Debt / Equity (Annual)0.76x
Current Ratio (Quarterly)1.92x
Enterprise Value$18.84M
Revenue / Share Growth (5Y)3.44%
Asset Turnover (TTM)1.79x
Book Value / Share Growth (5Y)-25.62%
Revenue / Employee (Annual)$566,400
Inventory Turnover (Annual)2.81x
Pretax Margin (Annual)-8.32%
Cash / Share (Annual)$0.35
3-Month Return Std Dev64.18%
Gross Margin (5Y Avg)41.10%
Net Income / Employee (TTM)$-35,200
ROE (Last FY)-90.15%
EPS Basic Excl Extra (Annual)$-0.26
P/FCF (TTM)40.72x
Receivables Turnover (TTM)7.78x
Total Debt / Equity (Quarterly)0.80x
EPS Incl Extra (TTM)$-0.19
Receivables Turnover (Annual)7.68x
ROI (TTM)-37.14%
P/S Ratio (TTM)0.37x
Pretax Margin (5Y Avg)-13.51%
Revenue / Share (Annual)$3.11
Tangible BV / Share (Annual)$0.23
Price vs S&P 500 (52W)-2.26%
Year-to-Date Return-1.75%
5-Day Price Return2.75%
EPS Normalized (Annual)$-0.26
ROA (5Y Avg)-20.44%
Net Profit Margin (Annual)-8.42%
Month-to-Date Return6.67%
Cash Flow / Share (TTM)$-0.34
EBITD / Share (Annual)$-0.12
Operating Margin (Annual)-4.88%
LT Debt / Equity (Annual)0.76x
ROI (5Y Avg)-80.46%
LT Debt / Equity (Quarterly)0.80x
EPS Basic Excl Extra (TTM)$-0.19
P/TBV (Quarterly)4.53x
P/B Ratio (Annual)4.26x
Inventory Turnover (TTM)3.46x
Pretax Margin (TTM)-6.03%
Book Value / Share (Annual)$0.28
Price vs S&P 500 (13W)-25.50%
Beta0.63x
P/FCF (Annual)2.46x
Revenue / Share (TTM)$3.04
ROE (TTM)-64.23%
52-Week Low$0.87
vGradeB
gGradeD
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.03est. -0.07
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.14
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IRIXIridex Corp | B | D | C | $1.12 |
| MDTMedtronic plc | B | C | C | $80.20 |
| MASIMasimo Corporation | D | D | B | $179.95 |
| LIVNLivaNova PLC Ordinary Shares | C | C | A | $79.39 |
| ITGRInteger Holdings Corporation | B | C | C | $90.98 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | $72.91 |
| AXGNAxogen, Inc. Common Stock | F | B | A | $43.00 |
| BLFSBioLife Solutions Inc. | F | B | B | $26.10 |
| CNMDCONMED Corporation | A | C | D | $34.77 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | $13.45 |
| CBLLCeriBell, Inc. Common Stock | D | A | C | $18.47 |
About
IRIDEX manufactures laser-based medical systems for ophthalmology, powered by proprietary Micropulse technology that provides competitive differentiation. The company generates revenue through sales of surgical consoles, delivery devices, glaucoma treatment systems, consumables, and support services, with additional exposure to veterinary and ENT markets. IRIDEX operates globally with primary revenue contributions from North America, Europe, and Asia/Pacific.